149 related articles for article (PubMed ID: 32300936)
1. Hemophagocytic Lymphohistiocytosis Occurring in Inflammatory Bowel Disease: Systematic Review.
Coburn ES; Siegel CA; Winter M; Shah ED
Dig Dis Sci; 2021 Mar; 66(3):843-854. PubMed ID: 32300936
[TBL] [Abstract][Full Text] [Related]
2. Infliximab Is Not Associated With Increased Risk of Malignancy or Hemophagocytic Lymphohistiocytosis in Pediatric Patients With Inflammatory Bowel Disease.
Hyams JS; Dubinsky MC; Baldassano RN; Colletti RB; Cucchiara S; Escher J; Faubion W; Fell J; Gold BD; Griffiths A; Koletzko S; Kugathasan S; Markowitz J; Ruemmele FM; Veereman G; Winter H; Masel N; Shin CR; Tang KL; Thayu M
Gastroenterology; 2017 Jun; 152(8):1901-1914.e3. PubMed ID: 28193515
[TBL] [Abstract][Full Text] [Related]
3. Hemophagocytic lymphohistiocytosis in inflammatory bowel disease: a nationwide analysis.
Mahmoud AA; Abdelhay A; Khamis A; Mostafa M; Shehadah A; Mohamed MS; Eltaher B; Malik T
Ann Hematol; 2023 Jul; 102(7):1705-1711. PubMed ID: 37093242
[TBL] [Abstract][Full Text] [Related]
4. Infection is the major trigger of hemophagocytic syndrome in adult patients treated with biological therapies.
Brito-Zerón P; Bosch X; Pérez-de-Lis M; Pérez-Álvarez R; Fraile G; Gheitasi H; Retamozo S; Bové A; Monclús E; Escoda O; Moreno A; López-Guillermo A; Khamashta MA; Ramos-Casals M;
Semin Arthritis Rheum; 2016 Feb; 45(4):391-9. PubMed ID: 26277577
[TBL] [Abstract][Full Text] [Related]
5. Systematic review: hepatosplenic T-cell lymphoma on biologic therapy for inflammatory bowel disease, including data from the Food and Drug Administration Adverse Event Reporting System.
Shah ED; Coburn ES; Nayyar A; Lee KJ; Koliani-Pace JL; Siegel CA
Aliment Pharmacol Ther; 2020 Mar; 51(5):527-533. PubMed ID: 31990422
[TBL] [Abstract][Full Text] [Related]
6. Systematic Review of Effects of Withdrawal of Immunomodulators or Biologic Agents From Patients With Inflammatory Bowel Disease.
Torres J; Boyapati RK; Kennedy NA; Louis E; Colombel JF; Satsangi J
Gastroenterology; 2015 Dec; 149(7):1716-30. PubMed ID: 26381892
[TBL] [Abstract][Full Text] [Related]
7. Are Biologics Safe in the Immediate Postoperative Period? A Single-Center Evaluation of Consecutive Crohn's Surgical Patients.
Lightner AL; Grass F; Alsughayer AM; Harmsen WS; Petersen M; Loftus EV
Dis Colon Rectum; 2020 Jul; 63(7):934-943. PubMed ID: 32149787
[TBL] [Abstract][Full Text] [Related]
8. Safety of Biologic Therapy in Older Patients With Immune-Mediated Diseases: A Systematic Review and Meta-analysis.
Borren NZ; Ananthakrishnan AN
Clin Gastroenterol Hepatol; 2019 Aug; 17(9):1736-1743.e4. PubMed ID: 30616024
[TBL] [Abstract][Full Text] [Related]
9. Association of Crohn's disease, thiopurines, and primary epstein-barr virus infection with hemophagocytic lymphohistiocytosis.
Biank VF; Sheth MK; Talano J; Margolis D; Simpson P; Kugathasan S; Stephens M
J Pediatr; 2011 Nov; 159(5):808-12. PubMed ID: 21722918
[TBL] [Abstract][Full Text] [Related]
10. Severe CMV-related pneumonia complicated by the hemophagocytic lymphohistiocytic (HLH) syndrome in quiescent Crohn's colitis: harmful cure?
Presti MA; Costantino G; Della Torre A; Belvedere A; Cascio A; Fries W
Inflamm Bowel Dis; 2011 Nov; 17(11):E145-6. PubMed ID: 21826767
[No Abstract] [Full Text] [Related]
11. Risk of Cancer in Paediatric onset Inflammatory Bowel Diseases: A Nation-wide Study From the epi-IIRN.
Atia O; Harel S; Ledderman N; Greenfeld S; Kariv R; Dotan I; Balicer R; Silverman B; Matz E; Levi Z; Waterman M; Fried I; Rowe JM; Turner D
J Crohns Colitis; 2022 Jun; 16(5):786-795. PubMed ID: 34791097
[TBL] [Abstract][Full Text] [Related]
12. Prior Immunogenicity to Anti-TNF Biologics Is Not Associated with Increased Anti-drug Antibodies to Vedolizumab or Ustekinumab.
Costable NJ; Borman ZA; Ji J; Dubinsky MC; Ungaro RC
Dig Dis Sci; 2022 Jun; 67(6):2480-2484. PubMed ID: 34021427
[TBL] [Abstract][Full Text] [Related]
13. Hemophagocytic lymphohistiocytosis: a review inspired by the COVID-19 pandemic.
Soy M; Atagündüz P; Atagündüz I; Sucak GT
Rheumatol Int; 2021 Jan; 41(1):7-18. PubMed ID: 32588191
[TBL] [Abstract][Full Text] [Related]
14. The role of interleukin-18 in the diagnosis and monitoring of hemophagocytic lymphohistiocytosis/macrophage activation syndrome - a systematic review.
Krei JM; Møller HJ; Larsen JB
Clin Exp Immunol; 2021 Feb; 203(2):174-182. PubMed ID: 33128796
[TBL] [Abstract][Full Text] [Related]
15. Efficacy of Infliximab in Crohn's Disease Patients with Prior Primary-Nonresponse to Tumor Necrosis Factor Antagonists.
Clark-Snustad KD; Singla A; Lee SD
Dig Dis Sci; 2019 Jul; 64(7):1952-1958. PubMed ID: 30815825
[TBL] [Abstract][Full Text] [Related]
16. Hemophagocytic Lymphohistiocytosis and Inflammatory Bowel Disease: Case Report and Systematic Review.
Brambilla B; Barbosa AM; Scholze CDS; Riva F; Freitas L; Balbinot RA; Balbinot S; Soldera J
Inflamm Intest Dis; 2020 Jun; 5(2):49-58. PubMed ID: 32596254
[TBL] [Abstract][Full Text] [Related]
17. No Benefit of Concomitant Immunomodulator Therapy on Efficacy of Biologics That Are Not Tumor Necrosis Factor Antagonists in Patients With Inflammatory Bowel Diseases: A Meta-analysis.
Yzet C; Diouf M; Singh S; Brazier F; Turpin J; Nguyen-Khac E; Meynier J; Fumery M
Clin Gastroenterol Hepatol; 2021 Apr; 19(4):668-679.e8. PubMed ID: 32629124
[TBL] [Abstract][Full Text] [Related]
18. Hemophagocytic Lymphohistiocytosis Associated With Cytomegalovirus Infection: 5 Cases and a Systematic Review of the Literature.
Chevalier K; Schmidt J; Coppo P; Galicier L; Noël N; Lambotte O
Clin Infect Dis; 2023 Jan; 76(2):351-358. PubMed ID: 35974465
[TBL] [Abstract][Full Text] [Related]
19. Hemophagocytic lymphohistiocytosis following pembrolizumab and bevacizumab combination therapy for cervical cancer: a case report and systematic review.
Zhai C; Jin X; You L; Yan N; Dong J; Qiao S; Zhong Y; Zheng Y; Pan H
BMC Geriatr; 2024 Jan; 24(1):32. PubMed ID: 38191289
[TBL] [Abstract][Full Text] [Related]
20. Colon Surgery Risk With Corticosteroids Versus Immunomodulators or Biologics in Inflammatory Bowel Disease Patients With Clostridium difficile Infection.
Solanky D; Pardi DS; Loftus EV; Khanna S
Inflamm Bowel Dis; 2019 Feb; 25(3):610-619. PubMed ID: 30260451
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
